The current limits of molecular diagnostics such as the PCR method do not allow for rapid screening and personalised care of cancers and viral diseases: health professionals and institutions are waiting for simple, rapid and cost-effective tests for patient screening and care. BrightSens Diagnostics will provide the solution to these needs by offering highly sensitive Point of Care tests.

Their patented technology, with its unique properties, is the fruit of 7 years of research supported to the tune of €2m by the prestigious European Research Council (ERC). Fluorescent, ultra-bright and ultra-sensitive nanoparticles make it possible to amplify the detection signal and therefore to measure very low concentrations of DNA/RNA (key biomarkers of disease) through simple measurement of fluorescence, without the use of costly instruments such as PCR equipment. Point of Care tests will revolutionise molecular diagnostics.